Trial Profile
Phase II study: Active specific immunotherapy with the 1e10 anti idiotype vaccine in the treatment of patients with advanced non small cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Oct 2020
Price :
$35
*
At a glance
- Drugs Racotumomab (Primary) ; Alum
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 01 May 2014 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
- 02 Oct 2012 Status changed from active, no longer recruiting to completed.
- 02 Nov 2010 New trial record